News & Views
New CMO to Drive In-House Programs to Clinic
Feb 08 2019 Read 257 Times
Dr Jose Saro has joined Avacta Group as Chief Medical Officer to lead the Group’s therapeutic development strategy and drive the in-house programmes into the clinic.
Bringing over 20 years’ experience in the pre-clinical, translational and early clinical development of oncology assets, spanning small molecules, biologics and drug conjugates, Dr Saro joins Avacta, the developer of Affimer® biotherapeutics and reagents, from Roche where he was Senior Translational Medicine Leader at the Roche Innovation Center Zurich in which he focused on immuno-oncology and the development of combination products.
Prior to this position Dr Saro was also Executive Director Oncology Global Development and Medical Affairs at Bristol Myers Squibb, based in Paris, leading and contributing to many oncology clinical development programmes; and formerly Executive Director of Translational Medicine and Early Clinical Development (Oncology) at Novartis. He also held senior positions at Eisai, and Wyeth and
spent several years as Vice President Oncology Clinical Development at PharmaMar, an oncology focused biotech.
Dr Jose Saro said: “Due to their simple structure, Affimer® proteins can be formatted to deliver the right characteristics required for the next generation of immuno-oncology therapeutics.There are many opportunities for such a platform technology, and the recent collaboration with Tufts University Medical School is one example of a potentially game changing approach that is possible with Affimers.
“I am very excited to be part of Avacta as it continues to develop such transformative approaches using the Affimer®platform, that I believe will be a huge benefit to many oncology patients who currently have limited therapeutic options.”
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In this edition Articles - Detection of molecular markers in aquatic sediments by ion profi les obtained by GC/MS system - Fighting the Resistance: How Rapid Microbial ID with MALDI MS and A...
View all digital editions
Feb 25 2019 Moscow, Russia
Feb 26 2019 Guangzhou, China
Feb 27 2019 Berlin, Germany
Mar 03 2019 Maryland, (Washington DC), USA
Mar 05 2019 London, UK